NEW YORK Michael Pearson, the former chief executive officer of Valeant Pharmaceuticals International (VRX.TO), has signed a consulting agreement with the drugmaker that will run through 2017 and pay him hundreds of thousands of dollars, according to the separation agreement filed with regulators.
Pearson, who left Valeant on May 2 after a year in which it had drawn scrutiny for its sharp drug price increases, financial relationship with a specialty pharmacy and accounting practices, can earn $83,333 a month this year as a consultant.
16:17 Why analysts think Kevin Johnson is the right replacement for Starbucks CEO Howard Schultz9
14:07 Study: Believing in Santa Claus could be damaging to children15
12:43 Outgoing Starbucks CEO Howard Schultz: Kevin Johnson better prepared to be CEO13
06:01 As Schultz Steps Down, Next Starbucks CEO Brings Tech Savvy11